Epidemiology of Mucopolysaccharidoses Update
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Constructing an Efficient Bacillus Subtilis Spore Display by Using
molecules Article Constructing an Efficient Bacillus subtilis Spore Display by Using Cohesin−Dockerin Interactions He Wang 1,*,†, Xiaomin Jiang 2,†, Yongchang Qian 3 and Lianghong Yin 3 1 School of Grain Science and Technology, Jiangsu University of Science and Technology, Zhenjiang 212100, China 2 School of Agricultural and Food Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 311300, China; [email protected] 3 School of Forestry and Biotechnology, Zhejiang Agriculture and Forestry University, Hangzhou 311300, China; [email protected] (Y.Q.); [email protected] (L.Y.) * Correspondence: [email protected]; Tel.: +86-511-84423559 † These authors contributed equally to this work. Abstract: Bacillus subtilis spore display has become a field of increasing interest in the past two decades. To improve the efficiency of B. subtilis spore display, its directed modification was performed based on the cellulosome architecture by introducing onto them divergent cohesin (Coh) modules that can specifically bind to the target enzyme bearing the matching dockerins (Doc). In this study, five different pairs of cohesins and dockerins, selected from four cellulolytic microbes, were examined for their capabilities in displaying a tetrameric enzyme β-galactosidase from Bacillus stearothermophilus IAM11001 on the surface of B. subtilis WB600 spores. Immunofluorescence microscopy, western blotting, dot blotting, and enzyme assay was applied to confirm its surface expression. All the resultant five Coh–Doc based spore display can hydrolyze o-nitrophenyl-β-D-galactopyranoside. Citation: Wang, H.; Jiang, X.; Qian, Further, the optimized Coh–Doc based spore display exhibited the highest display efficiency. Overall, Y.; Yin, L. Constructing an Efficient the results of current study may open new perspectives on the use of Coh–Doc interaction, which Bacillus subtilis Spore Display by will find application in improving the efficiency of B. -
Bacteria Belonging to Pseudomonas Typographi Sp. Nov. from the Bark Beetle Ips Typographus Have Genomic Potential to Aid in the Host Ecology
insects Article Bacteria Belonging to Pseudomonas typographi sp. nov. from the Bark Beetle Ips typographus Have Genomic Potential to Aid in the Host Ecology Ezequiel Peral-Aranega 1,2 , Zaki Saati-Santamaría 1,2 , Miroslav Kolaˇrik 3,4, Raúl Rivas 1,2,5 and Paula García-Fraile 1,2,4,5,* 1 Microbiology and Genetics Department, University of Salamanca, 37007 Salamanca, Spain; [email protected] (E.P.-A.); [email protected] (Z.S.-S.); [email protected] (R.R.) 2 Spanish-Portuguese Institute for Agricultural Research (CIALE), 37185 Salamanca, Spain 3 Department of Botany, Faculty of Science, Charles University, Benátská 2, 128 01 Prague, Czech Republic; [email protected] 4 Laboratory of Fungal Genetics and Metabolism, Institute of Microbiology of the Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic 5 Associated Research Unit of Plant-Microorganism Interaction, University of Salamanca-IRNASA-CSIC, 37008 Salamanca, Spain * Correspondence: [email protected] Received: 4 July 2020; Accepted: 1 September 2020; Published: 3 September 2020 Simple Summary: European Bark Beetle (Ips typographus) is a pest that affects dead and weakened spruce trees. Under certain environmental conditions, it has massive outbreaks, resulting in attacks of healthy trees, becoming a forest pest. It has been proposed that the bark beetle’s microbiome plays a key role in the insect’s ecology, providing nutrients, inhibiting pathogens, and degrading tree defense compounds, among other probable traits. During a study of bacterial associates from I. typographus, we isolated three strains identified as Pseudomonas from different beetle life stages. In this work, we aimed to reveal the taxonomic status of these bacterial strains and to sequence and annotate their genomes to mine possible traits related to a role within the bark beetle holobiont. -
Pharmacological Analysis of Cyclooxygenase-1 in Inflammation
Proc. Natl. Acad. Sci. USA Vol. 95, pp. 13313–13318, October 1998 Pharmacology Pharmacological analysis of cyclooxygenase-1 in inflammation CHRISTOPHER J. SMITH,YAN ZHANG,CAROL M. KOBOLDT,JERRY MUHAMMAD,BEN S. ZWEIFEL,ALEX SHAFFER, JOHN J. TALLEY,JAIME L. MASFERRER,KAREN SEIBERT, AND PETER C. ISAKSON* Searle Research and Development, 700 Chesterfield Parkway North, St. Louis, MO 63198 Communicated by Philip Needleman, Monsanto Company, St. Louis, MO, August 25, 1998 (received for review May 11, 1998) ABSTRACT The enzymes cyclooxygenase-1 and cycloox- and is expressed constitutively in most tissues and cells (17), ygenase-2 (COX-1 and COX-2) catalyze the conversion of although it can be induced in some cell lines under certain arachidonic acid to prostaglandin (PG) H2, the precursor of conditions (18). A second, inducible, form of COX was PGs and thromboxane. These lipid mediators play important hypothesized to exist on the basis of the finding of a glucocor- roles in inflammation and pain and in normal physiological ticoid-regulated increase in COX activity observed in vitro and functions. While there are abundant data indicating that the in vivo in response to inflammatory stimuli (19, 20). The inducible isoform, COX-2, is important in inflammation and isolation of a distinct gene and enzyme for COX-2 confirmed pain, the constitutively expressed isoform, COX-1, has also this hypothesis and led to the supposition that selective inhi- been suggested to play a role in inflammatory processes. To bition of inducible COX-2 would be anti-inflammatory, while address the latter question pharmacologically, we used a preserving the physiological functions of COX-1 derived PGs. -
Quality Control in Immunocytochemistry: Experiences with the Oestrogen Receptor Assay J Clin Pathol: First Published As 10.1136/Jcp.45.2.120 on 1 February 1992
120 J Clin Pathol 1992;45:120-124 Quality control in immunocytochemistry: Experiences with the oestrogen receptor assay J Clin Pathol: first published as 10.1136/jcp.45.2.120 on 1 February 1992. Downloaded from F T Bosman, A F P M de Goeij, M Rousch Abstract ted specificity to be produced, and the develop- Aims: To evaluate the feasibility of an ment of very sensitive second step reagents. As interlaboratory quality control pro- a consequence, almost every surgical pathology gramme in immunohistochemistry. laboratory routinely uses immunocyto- chemistry on a daily basis. As recently Methods: Several pathology laboratories ' were asked to carry out immunohisto- indicated by Elias et al, however, an important chemical oestrogen receptor staining on a source of variability in the performance of set of freeze dried cryostat sections of immunocytochemistry techniques is the vari- breast cancer tissue. The sections and ation among laboratories in tissue processing protocols for staining and semi- and histochemical procedures. This could be quantitative scoring were mailed to the improved by standardisation, monitored by participating laboratories in two trials. quality control programmes. The oestrogen receptor content of the A typical example of an immunocyto- breast cancer samples was determined by chemical test which requires such an approach radioligand binding assay on the tumour is the evaluation of the oestrogen receptor cytosol. content in breast cancer. About 60% of Results: In the first trial 11 laboratories patients with an oestrogen receptor positive (response rate 60%) participated. Eight tumour will respond to some form ofendocrine (73%) of the participants scored within a treatment; less than 10% of oestrogen receptor 95% confidence interval and all but one negative neoplasms respond.23 Expression of correctlyclassified thetumour as receptor oestrogen receptor protein may also be regar- positive. -
Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma
cancers Article Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma 1, 1, 1 1 1 Lan Wang y, Anudeep Yekula y, Koushik Muralidharan , Julia L. Small , Zachary S. Rosh , Keiko M. Kang 1,2, Bob S. Carter 1,* and Leonora Balaj 1,* 1 Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA; [email protected] (L.W.); [email protected] (A.Y.); [email protected] (K.M.); [email protected] (J.L.S.); [email protected] (Z.S.R.); [email protected] (K.M.K.) 2 School of Medicine, University of California San Diego, San Diego, CA 92092, USA * Correspondence: [email protected] (B.S.C.); [email protected] (L.B.) These authors contributed equally. y Received: 11 March 2020; Accepted: 7 May 2020; Published: 13 May 2020 Abstract: Sequencing studies have provided novel insights into the heterogeneous molecular landscape of glioblastoma (GBM), unveiling a subset of patients with gene fusions. Tissue biopsy is highly invasive, limited by sampling frequency and incompletely representative of intra-tumor heterogeneity. Extracellular vesicle-based liquid biopsy provides a minimally invasive alternative to diagnose and monitor tumor-specific molecular aberrations in patient biofluids. Here, we used targeted RNA sequencing to screen GBM tissue and the matched plasma of patients (n = 9) for RNA fusion transcripts. We identified two novel fusion transcripts in GBM tissue and five novel fusions in the matched plasma of GBM patients. The fusion transcripts FGFR3-TACC3 and VTI1A-TCF7L2 were detected in both tissue and matched plasma. -
DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic) -
Uptake of -(L)-Iduronidase Produced by Retrovirally Transduced
Gene Therapy (1997) 4, 63–75 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Uptake of a-(L)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro K Stewart1, OA Brown1, AE Morelli1, LJ Fairbairn2, LS Lashford2,3, A Cooper4, CE Hatton4, TM Dexter2, MG Castro1 and PR Lowenstein1 1Molecular Medicine Unit, Department of Medicine, University of Manchester School of Medicine; 2CRC Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester; 3Academic Unit of Pediatric Oncology, Christie Hospital NHS Trust, Manchester; and 4Willink Biochemical Genetics Unit, Royal Manchester Children’s Hospital, Manchester, UK The uptake of recombinant a-(L)-iduronidase into glial and higher in actively dividing or immature brain cells. Conse- neuronal cells, produced by retrovirally transduced NIH3T3 quently, (1) neuronal metabolism ought to be capable of fibroblasts, was studied. We demonstrate that: (1) neuronal cross correction by enzyme provided by genetically engine- and glial cells take up a-(L)-iduronidase released into the ered and transplanted cells provided by bone marrow medium by retrovirally transduced fibroblasts expressing transplantation (BMT); (2) that BMT could have a more high levels of a-(L)-iduronidase; (2) both glial and neuronal beneficial effect on neurological function if performed as cells express the cation independent mannose-6-phos- early as possible; and (3) given that the uptake mechanism phate receptor responsible for lysosomal enzyme uptake; of glial cells has a higher capacity, it might be easier to and (3) uptake of the lysosomal enzyme can be blocked target diseases like the leukodystrophies in which lysoso- by excess free mannose-6-phosphate, but not glucose-6- mal enzymes are needed in glial cells, compared to dis- phosphate. -
Long-Term Outcomes of Systemic Therapies for Hurler Syndrome: an International Multicenter Comparison
© American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison Julie B. Eisengart, PhD1, Kyle D. Rudser, PhD2, Yong Xue, MD, PhD3, Paul Orchard, MD4, Weston Miller, MD4, Troy Lund, MD, PhD4, Ans Van der Ploeg, MD, PhD5, Jean Mercer, RGN, RSCN6, Simon Jones, MBChB7, Karl Eugen Mengel, MD8, Seyfullah Gökce, MD8, Nathalie Guffon, MD9, Roberto Giugliani, MD, PhD10, Carolina F.M. de Souza, MD, PhD10, Elsa G. Shapiro, PhD1,11 and Chester B. Whitley, PhD, MD12 Purpose: Early treatment is critical for mucopolysaccharidosis type I Results: Survival was worse when comparing ERT versus HCT, and (MPS I), justifying its incorporation into newborn screening. Enzyme Untreated versus ERT. The cumulative incidences of hydrocephalus replacement therapy (ERT) treats MPS I, yet presumptions that ERT – and cervical spinal cord compression were greater in ERT versus HCT. cannot penetrate the blood brain barrier (BBB) support recommen- Findings persisted in the sensitivity analysis. dations that hematopoietic cell transplantation (HCT) treat the severe, neurodegenerative form (Hurler syndrome). Ethics precludes rando- Conclusion: As newborn screening widens treatment opportunity for mized comparison of ERT with HCT, but insight into this comparison Hurler syndrome, this examination of early treatment quantifies some is presented with an international cohort of patients with Hurler ERT benefit, supports presumptions about BBB impenetrability, and syndrome who received long-term ERT from a young age. aligns with current guidelines to treat with HCT. Methods: Long-term survival and neurologic outcomes were Genet Med compared among three groups of patients with Hurler syndrome: 18 advance online publication 8 March 2018 treated with ERT monotherapy (ERT group), 54 who underwent HCT (HCT group), and 23 who received no therapy (Untreated). -
Open CR-Thesis-Final-Final.Pdf
The Pennsylvania State University The Graduate School IDENTIFICATION OF GENETIC FACTORS THAT AFFECT NEURONAL PATTERNING, FUNCTION, AND DISEASE IN DROSOPHILA MELANOGASTER A Dissertation in Biochemistry, Microbiology, and Molecular Biology by Claire Elizabeth Reynolds Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2017 The dissertation of Claire Elizabeth Reynolds was reviewed and approved* by the following: Scott B Selleck Professor of Biochemistry & Molecular Biology Dissertation Co-Advisor Chair of Committee Santhosh Girirajan Assistant Professor of Biochemistry & Molecular Biology Assistant Professor of Anthropology Dissertation Co-Advisor Joseph Reese Professor of Biochemistry & Molecular Biology Marylyn Ritchie Director, Center for Systems Genomics Director, Biomedical & Translational Informatics Program of Geisinger Research Professor of Biochemistry & Molecular Biology Richard Ordway Professor of Molecular Neuroscience and Genetics Wendy Hanna-Rose Associate Professor of Biochemistry & Molecular Biology Interim Head of the Department of Biochemistry and Molecular Biology *Signatures are on file in the Graduate School ii ABSTRACT Heparan Sulfate Proteoglycans (HSPGs) are required for normal synaptic development at the Drosophila melanogaster larval neuromuscular junction (NMJ). When enzymes required for biosynthesis of HSPGs are inhibited through mutations of RNA interference, a variety of morphological and electrophysiological defects are observed at the NMJ. These defects included changes in the post-synaptic specialization of the muscle (the SSR), loss of mitochondria from the sub-synaptic cytosol, and abnormal mitochondrial morphology. Identification of autophagic regulation as the mechanism by which HSPGs influenced synaptic properties was the foundation of this dissertation. The present work more fully characterizes the influence of HSPG function on autophagic markers in muscle tissue. -
Pathophysiology of Mucopolysaccharidosis
Pathophysiology of Mucopolysaccharidosis Dr. Christina Lampe, MD The Center for Rare Diseases, Clinics for Pediatric and Adolescent Medicine Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany Inborn Errors of Metabolism today - more than 500 diseases (~10 % of the known genetic diseases) 5000 genetic diseases - all areas of metabolism involved - vast majority are recessive conditions 500 metabolic disorders - individually rare or very rare - overall frequency around 1:800 50 LSD (similar to Down syndrome) LSDs: 1: 5.000 live births MPS: 1: 25.000 live births 7 MPS understanding of pathophysiology and early diagnosis leading to successful therapy for several conditions The Lysosomal Diseases (LSD) TAY SACHS DIS. 4% WOLMAN DIS. ASPARTYLGLUCOSAMINURIA SIALIC ACID DIS. SIALIDOSIS CYSTINOSIS 4% SANDHOFF DIS. 2% FABRY DIS. 7% POMPE 5% NIEMANN PICK C 4% GAUCHER DIS. 14% Mucopolysaccharidosis NIEMANN PICK A-B 3% MULTIPLE SULPH. DEF. Mucolipidosis MUCOLIPIDOSIS I-II 2% Sphingolipidosis MPSVII Oligosaccharidosis GM1 GANGLIOSIDOSIS 2% MPSVI Neuronale Ceroid Lipofuszinois KRABBE DIS. 5% MPSIVA others MPSIII D A-MANNOSIDOSIS MPSIII C MPSIIIB METACHROMATIC LEUKOD. 8% MPS 34% MPSIIIA MPSI MPSII Initial Description of MPS Charles Hunter, 1917: “A Rare Disease in Two Brothers” brothers: 10 and 8 years hearing loss dwarfism macrocephaly cardiomegaly umbilical hernia joint contractures skeletal dysplasia death at the age of 11 and 16 years Description of the MPS Types... M. Hunter - MPS II (1917) M. Hurler - MPS I (1919) M. Morquio - MPS IV (1929) M. Sanfilippo - MPS III (1963) M. Maroteaux-Lamy - MPS IV (1963) M. Sly - MPS VII (1969) M. Scheie - MPS I (MPS V) (1968) M. Natowicz - MPS IX (1996) The Lysosome Lysosomes are.. -
Mini-Review on “Molecular Diagnosis of 65 Families With
Mashima R, Okuyama T. J Rare Dis Res Treat. (2016) 2(1): 43-46 Journal of www.rarediseasesjournal.com Rare Diseases Research & Treatment Mini-Review Open Access Mini-review on “Molecular diagnosis of 65 families with mucopoly- saccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural stud- ies on iduronate-2-sulfatase.” Ryuichi Mashima1* and Torayuki Okuyama1,2 1Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan 2Center for Lysosomal Storage Disorders, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan ABSTRACT Article Info Article Notes Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM #309900) Received: November 29, 2016 is an X-linked congenital disorder characterized by an accumulation of Accepted: December 28, 2016 glycosaminoglycans in the body. Accumulating evidence has suggested that the prevalence of the severe type of MPS II is almost 70%. In addition, novel *Correspondence: mutations that are relevant to MPS II pathogenesis are being increasingly Ryuichi Mashima, Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10- discovered, so the databases of genetic data regarding pathogenic mutations 1 Okura, Setagaya-ku, Tokyo 157-8535, Japan, E-mail: have been growing. We have recently reported a collection of 16 novel [email protected] pathogenic mutations of the iduronate-2-sulfatase (IDS) gene in 65 families with MPS II in a Japanese population1. We also proposed that a homology- © 2016 Ryuichi Mashima. -
Beta-Galactosidase Deficiency: Beta-Galactosidase Activity, Leukocytes Test Code: LO Turnaround Time: 7 Days - 10 Days CPT Codes: 82657 X1
2460 Mountain Industrial Boulevard | Tucker, Georgia 30084 Phone: 470-378-2200 or 855-831-7447 | Fax: 470-378-2250 eglgenetics.com Beta-Galactosidase Deficiency: Beta-Galactosidase Activity, Leukocytes Test Code: LO Turnaround time: 7 days - 10 days CPT Codes: 82657 x1 Condition Description Beta-galactosidase deficiency is associated with three distinct autosomal recessive lysosomal storage disorders: GM1 gangliosidosis (GM1), mucopolysaccharidosis type IVB (MPS IVB), and galactosialidosis. GM1 and MPS IVB are referred to as GLB1-related disorders as they are the result of biallelic mutations in GLB1. Galactosialidosis is caused by mutations in CTSA (cathepsin A) and results in decreased activity of beta-galactosidase and neuraminidase. Deficiency of beta-galactosidase leads to the accumulation of sphingolipid intermediates in lysosomes of neuronal tissue, resulting in the CNS deterioration typical of GM1. Deficiency of this enzyme also leads to accumulation of the glycosaminoglycan (GAG) keratan sulfate in cartilage which is suspected to cause the skeletal findings associated with MPS IVB. Patients with GM1 have a characteristic abnormal pattern of oligosaccharide elevations in urine detectable by TLC and MALDI-TOF mass spectrometry. Patients with MPS IVB have detectable bands of keratan sulfate by GAG analysis with TLC. Keratan sulfate is also present in MPS IVA and the clinical presentation of MPS IVB is not distinguishable from that of MPS IVA. Patients with galactosialidosis also have characteristic oligosaccharide elevations and decreased neuraminidase 1 enzyme levels. Neuraminidase testing and molecular analysis of CTSA is recommended to confirm a diagnosis of galactosialidosis. Determination of beta-galactosidase levels is not recommended for carrier detection. GM1 gangliosidosis has been classified into three major clinical forms according to the age of onset and severity of symptoms: type I (infantile), type II (late infantile/juvenile) and type III (adult).